Inspira Technologies OXY Deploys, Initiates Structured Commercial Evaluation Of Its FDA-Cleared INSPIRA ART100 System

+0.91% Pre

Inspira Technologies Oxy B.H.N. Ltd.

IINN

0.57

+0.91%

0.00% Pre

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration ("FDA")-cleared INSPIRA™ ART100 system (the "ART100") at a new and additional leading U.S. academic medical center.

The partnering institution is a prominent health system serving a large patient population, and is ranked among New York State's top 10 hospitals in Newsweek's World's Best Hospitals 2025 ranking.

This deployment expands Inspira Technologies' presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company's FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.